Healthcare with Confidence
Leading Rheumatologists, Modern Treatments and Innovations of 2026 in Israel
Looking for the best rheumatologist in Israel in 2026 usually means one thing: finding a specialist who matches your exact condition and offers the full spectrum of care—conservative treatment, advanced targeted medications, and long-term monitoring with a clear plan.
Today’s rheumatology is built around “treat-to-target” care: controlling early inflammation, preventing damage, and improving quality of life—often with stepwise therapy aligned with major international recommendations for conditions like rheumatoid arthritis, lupus, spondyloarthritis, psoriatic arthritis, and vasculitis.
What’s Innovative in Israeli Rheumatology in 2026?
Innovation usually means safer, more personalized care—not just new drugs:
- CAR-T Cell Therapy recently is being explored and used by the leading Israeli hospitals and top centers in the USA for autoimmune and rheumatologic diseases, such as lupus, rheumatoid arthritis, scleroderma, inflammatory myopathies, ANCA-associated vasculitis, Sjögren’s syndrome and others. ⇒ More details about CAR T Therapy for autoimmune diseases in Israel
- Earlier, tighter disease control strategies (especially in RA)
- Better safety frameworks: infection screening/prophylaxis and vaccination planning before immunosuppressive therapy
- Smarter risk-based medication choices, including careful use of JAK inhibitors in higher-risk patients
- More precise phenotyping (which joints/entheses/spine/skin/organs are involved) to match therapy (e.g., PsA and SLE updates)
Best Israeli Rheumatologists in Israel 2026

Prof. Pnina Langevitz – Senior rheumatologist at Sheba Medical Center, Tel Hashomer. Prof. Langevitz has managed the rheumatology unit for many years.
The doctor is recognized in the Forbes list of Israel’s top physicians.

Prof. Merav Lidar – Head of Rheumatology Department, Sheba Medical Center. President of the Israeli Society of Rheumatology in Israel.
The doctor is recognized in the Forbes list of Israel’s top physicians.
Book a Rheumatology Consultation in Israel Online or In Person
If you need a second opinion, a diagnosis confirmation, or an updated treatment plan for arthritis, lupus, vasculitis, scleroderma, myositis, gout, or osteoporosis, we can help arrange:
- Online expert consultation (document + imaging review), or
- In-person appointment in Israel with the right subspecialist.
To start consultation, please send:
A brief timeline of symptoms and prior diagnoses
- Blood tests (CBC, CRP/ESR, kidney/liver function; autoantibodies)
- Imaging reports (X-ray/ultrasound/MRI/CT)
- Medication list (including previous biologics/DMARDs and response)
- Any hospital discharge summaries or biopsy/pathology (if relevant)
Rheumatoid Arthritis or RA, Early Inflammatory Arthritis 2026
RA is one of the most common reasons to see a rheumatologist.
- Conservative care: anti-inflammatory pain control when needed, physical therapy, joint protection, smoking cessation, weight and cardiovascular risk management.
- Modern therapy: DMARDs (disease-modifying drugs) and—if needed—biologics or targeted oral therapies, guided by updated RA management recommendations.
Rheumatology Innovation 2026 in practice: tighter control strategies – treat-to-target, earlier escalation for active disease, and smarter safety screening—especially for people with cardiovascular risk factors or cancer history.
Axial Spondyloarthritis, Ankylosing Spondylitis and Back Inflammation 2026
If you have chronic inflammatory back pain, stiffness, or sacroiliac inflammation, this is the right subspecialist.
- Conservative care: tailored exercise/physiotherapy programs, posture and mobility work, NSAIDs when appropriate.
- Modern therapy: biological and targeted treatments for persistent active disease, following the ASAS-EULAR management approach.
Psoriatic Arthritis – PsA and Arthritis with Psoriasis 2026
PsA can affect joints, tendons (enthesitis), spine, and skin.
- Conservative care: rehab, weight management, short-term symptom relief, and close coordination with dermatology.
- Modern therapy: stepwise DMARDs and advanced targeted options for different PsA patterns, reflected in the latest EULAR PsA recommendations.
Systemic Lupus Erythematosus or SLE and Lupus Nephritis 2026
This subspecialty focuses on complex autoimmune disease affecting joints, skin, kidneys, blood, and more.
- Conservative care: sun protection, cardiovascular prevention, bone protection, careful monitoring of labs and organ function.
- Modern therapy: structured, guideline-based treatment plans, including long-term baseline therapy when appropriate and escalation based on organ involvement—captured in the updated EULAR SLE recommendations.
Vasculitis and ANCA-Associated Vasculitis 2026
Vasculitis can be urgent and organ-threatening, affecting kidneys, lungs, nerves, sinuses, and skin.
- Conservative care: rapid diagnosis, coordinated care with nephrology/pulmonology/ENT, infection prevention planning.
- Modern therapy: evidence-based induction and maintenance strategies (often including immunosuppressive regimens with structured steroid tapering), aligned with EULAR’s 2022 update for ANCA-associated vasculitis.
Systemic Sclerosis – Scleroderma, Connective Tissue Disease related Lung 2026
This subspecialty often overlaps with pulmonology and cardiology due to ILD and pulmonary hypertension risks.
- Conservative care: Raynaud’s management, skin/hand care, reflux control, rehab, close heart–lung screening.
- Modern therapy: more targeted treatment pathways for key organ domains are emphasized in newer EULAR systemic sclerosis recommendations.
Myositis – Polymyositis and Dermatomyositis, Muscle Inflammation 2026
Patients may have weakness, elevated muscle enzymes, skin rashes, or lung involvement.
- Conservative care: physiotherapy, nutrition support, osteoporosis prevention if steroids are used.
- Modern therapy: immunosuppressive strategies and escalation options for refractory disease, including IVIG in selected cases—reflected across contemporary guidance and reviews.
Crystal Arthritis: Gout, CPPD – Pseudogout 2026
These conditions can mimic infection or inflammatory arthritis.
- Conservative care: dietary counseling, weight and metabolic risk management, trigger management, and clear flare plans.
- Modern therapy: treat-to-target urate lowering for gout and imaging-supported diagnosis/management approaches consistent with EULAR guidance.
Osteoporosis, Steroid Bone Loss & Metabolic Bone Disease 2026
Often managed by rheumatologists—especially when autoimmune disease or steroids raise fracture risk.
- Conservative care: vitamin D/calcium optimization, resistance training, fall prevention, medication review.
- Modern therapy: structured prevention/treatment when glucocorticoids are used, based on updated ACR guidance.
Osteoarthritis, Fibromyalgia and Chronic Pain Overlap 2026
Not all pain is inflammatory—and top rheumatologists are skilled at distinguishing “inflammation” from “wear-and-tear” or central pain syndromes.
- Conservative care: exercise therapy, sleep optimization, pacing strategies, mental health support when needed.
- Modern therapy: evidence-based non-surgical OA strategies and multi-modal fibromyalgia care are emphasized in major rheumatology guidance.
Pregnancy, Fertility and Family Planning in Rheumatic Disease 2026
In 2026, high-level rheumatology care includes proactive planning for pregnancy and safe medication choices.
- Conservative care: timing disease control before conception, coordinated OB care.
- Modern practice: medication planning before and during pregnancy and lactation is supported by updated EULAR recommendations.
How to Choose Best Rheumatologist in Israel?
Choose a experienced doctor who can provide:
- Subspecialty focus (arthritis, lupus, vasculitis, osteoporosis, etc.)
- Full range of options (lifestyle + medications + biologics/targeted therapies, not “one-size-fits-all”)
- Safety-first monitoring (infection screening/vaccines, labs, imaging, side-effect prevention)
- Shared decision-making (your goals, pregnancy plans, work/quality of life, comorbidities)
- Access to clinical trials when standard therapies aren’t enough



